Linperlisib combo for advanced NK/T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ENKTL (extranodal NK/T-cell lymphoma).
- Your lymphoma has either come back after treatment, or you are newly diagnosed with stage III or IV disease.
- You need to have at least one tumor that can be seen on a scan (like a CT or PET scan).
- You should be able to take care of yourself (ECOG score 0–2) and expected to live more than 3 months.
- Your blood counts, kidney and liver function must be within certain limits (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a new drug, linperlisib, combined with standard chemotherapy (CHOP) for people newly diagnosed with a rare type of T-cell lymphoma (nTFHL) who plan to have a stem cell transplant. It aims to see if this combination is safe and effective.
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
Hear when a new Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.